Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020.

ABSTRACT:

Importance

Reported cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection likely underestimate the prevalence of infection in affected communities. Large-scale seroprevalence studies provide better estimates of the proportion of the population previously infected.

Objective

To estimate prevalence of SARS-CoV-2 antibodies in convenience samples from several geographic sites in the US.

Design, setting, and participants

This cross-sectional study performed serologic testing on a convenience sample of residual sera obtained from persons of all ages. The serum was collected from March 23 through May 12, 2020, for routine clinical testing by 2 commercial laboratory companies. Sites of collection were San Francisco Bay area, California; Connecticut;

SUBMITTER: Havers FP 

PROVIDER: S-EPMC12507447 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature